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I. INTRODUCTION 
1. Non-alcoholic fatty liver disease (= NAFLD) 
1.1   Definition, etiology and histology 
Definition 
Non-acloholic fatty liver disease (NAFLD) is a broad term used to describe a whole 
spectrum of liver diseases that ranges from simple steatosis to non-alcoholic 
steatohepatitis, the extreme form of NAFLD which is regarded as major cause of 
non-alcoholic, non-cholestatic cirrhosis of the liver and probably hepatocellular 
cancer (Clark 2003, Bugianesi 2002). The daily consumption of alcohol must not 
exceed 10g for female or 20g for male patients with NAFLD (Younossi 2008).  
 
Although often being used synonymly steatosis, fatty liver and steatohepatitis are 
three different, histologically well defined terms: if less then 50% of all hepatocytes 
contain fat storage, the histological finding is steatosis. In accordance, a stake of 
more than 50% of all hepatocytes containing fatty storage or a fat portion exceeding 
5% of the liver tissue is defined as fatty liver. Steatohepatitis is a combination of 
hepatocyte damage (e.g. obeseness, ballooning, apoptosis) and an inflammatory 
compoment (Neutrophilic infiltration, Monocytes) or fibrosis (Dancygier 2006). 
 
Etiology 
The exact pathogenesis of non-alcoholic steatohepatitis is not exactly clarified. The 
current explanation model for the pathogenesis of NASH is a two-hit-hypothesis that 
was proposed in 1998 by Day and James (Day 1998). The first hit in the progress of 
NAFLD is hepatocellular steatosis based on insulin resistance, the second hit means 
necroinflammatory mechanisms that lead to liver injury (Charlton 2002). 
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To understand insulin resistance, the basic physiology of insulin metabolism is 
explained in the following: Insulin is the most potent hormone within the human 
organism to lower serum glucose levels. It is secreted by !-cells, i.e. special cells in 
Islets of Langerhans located in the pancreas if blood glucose levels exceed around 
5mmol/ l.  Physiologically, insulin binds to a special protein expressed on the cell 
surface, the insulin receptor. By binding to this transmembrane receptor, a signalling 
pathway is started that mediates the fusion of vesicles containing special receptors 
for glucose transportation, i.e. GLUT-4-transporters. These GLUT-4-transporters are 
not expressed permanently only in presence of insulin receptor activity. This is an 
effective mechanism to lower blood glucose levels to approximately 5mmol/ l 
(Shepherd 1999). 
 
Within the human organism, there are different types of glucose transporters. This is 
important to understand why insulin is still highly effective in hepatic cells but not in 
peripheral muscle- and adipose tissue in insulin resistance. While muscle cells and 
fat cells express mainly above mentioned insulin dependent GLUT-4 transporters, 
hepatic cells mainly express insulin independent GLUT-2-transporters. That means, 
GLUT-2-transporters are expressed independently from insulin levels. 
 
Figure 1 illustrates the development of insulin resistance. A combination of 
exogenous factors like overnutrition and lower muscular activity, hormonal 
changes – especially insulin resistance – and possibly genetic disposition may 
lead to a non-alcoholic hepatocellular steatosis . As this combination is common in 
patients with metabolic syndrome, the epidemiologic correlation of NAFLD and the 
metabolic syndrome can be easily understood. 
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Overnutrition and fewer muscular activity lead to an increase of adipose tissue and 
with it to obesity. Proteohormons built in adiopocytes, i.e. spezial cells in fatty tissue, 
are called adipokines. The most important member of this cytokine family is 
adiponectin. Adiponectin enhances cellular sensibility to insulin. Obesity is 
considered as low-grade-inflammation of fatty tissue with higher infiltration of 
activated macrophages. Macrophages may inhibit the differentiation of adipocytes 
and by this lead to a modified adipokine secretion and by this to lower levels of 
adiponectin (Heilbronn 2008). Lower levels of adiponectin lead to lower sensibility to 
insulin and with it to insulin resistance (Renaldi 2009).  
 
Other cytokines secreted by adipose tissue are TNF-! (tumor necrosis factor), 
Interleukin-6, leptin and resistin. Higher levels of TNF-! and IL-6 can be found in fat 
Fig. 1: Etiology of insulin resistance 
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tissue of obese patients. These proinflammatory cytokines also disrupt normal insulin 
action in fat- and muscle cells. TNF-! worsens insulin resistance via activation of 
IKK-!, c-Jun N-terminal kinase (Farrell 2005). Adiponektin is a potent TNF-!-
neutralizing and anti-inflammatory adipokine. Furthermore, adiponketin induces anti-
inflammatory cytokines, like Interleukin-10 (Tilg 2006). This, again, shows the 
importance of adiponektine for prevention of insulin resistance. 
 
In the beginning of insulin resistance "-cells compensatorily secrete more insulin to 
decrease high blood glucose levels. This itself leads to insulin resistance by 
downregulation of the insulin receptor and with it to downregulation of GLUT-4 (type 
four glucose transporter) (Flores-Riveros 1993). Therefore, peripheral glucose uptake 
is reduced and serum glucose levels increases again. As the GLUT-2-transporter 
expressed on hepatic cells is not insulin dependent and consequently not 
downregulated, hepatic cells take up glucose permanently. Within a hepatocyte, 
glucose binds to the ChREBP-transcription factor (carbohydrate response element 
binding protein) and induces glucose degradation to Acetyl-CoA, the starting product 
of fatty-acid synthesis (Iizuka 2008). 
 
Insulin itself activates the SREBP-1c-transcription factor (sterol regulatory element 
binding protein) and induces the synthesis of enzymes of the fatty-acid-synthesis 
(Guillou 2008).  
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Peripheral insulin resistance leads to upregulated lipolysis in fatty tissue. 
Physiologically, insulin mediates downregulation of lipolysis. Due to the 
downregulation of insulin receptors and reduced insulin sensibility lipolysis can not be 
downregulated. Higher lipolysis entails higher levels of free fatty acids (FFA) in 
serum. Increased serum-FFA-levels lead to higher FFA-uptake in hepatocytes.  
Intracellular FFA bind to the PPAR"-transcription factor which induces the synthesis 
of enzymes for oxidative degradation of FFA to their building blocks Acetyl-CoA, i.e. 
!-oxidation. Thereby, the increased intracellular concentration of FFA can be 
compensated. In obese patients, the PPAR"-transcription factor is fewer expressed, 
probably because of lower adiponectin-levels. Therefore, the intracellular FFA-
concentration increases. Intracellular FFA, either de-novo-synthesized or directly 
uptaken, are processed to triglycerides.  
Fig. 2: Insulin resistane. FFA = free fatty acids, TG = triglycerides 
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To achieve a new stady steate and to regulate the intracellular triglyceride 
concentration, surplus triglycerides are either bound to and secreted as very low 
density lipoproteins (VLDL) or degradated by increased !-oxidation. 
 
Another pathway for decreasing high FFA levels is exporting them by lipoproteins. 
Lipoproteins are special proteins for transportation of lipophil substances like 
triglycerides, fatty acids and cholesterin in hydrophil blood. For stabilisation of VLDL-
chylomicrons Apolipoprotein B100 is needed. High insulin levels lead to increased 
intracellular degradation of Apolipoprotein B100 (Charlton 2002). In obese patients 
with permanent high insulin levels, VLDLs can not be stabilized and by this 
intracellular triglycerides can not be transported away and accumulate in hepatocytes 
and lead to hepatic steatosis. Figure 2 summaries the link between insulin resistance 
and steatosis hepatis. 
 
The above mentioned increased !-oxidation is an alternative pathway do limitate 
further lipid accumulation in hepatic cells. Increased mitochondrial !-oxidation could 
be proven in NASH patients (Miele 2003). 
 
As already said, hepatic steatosis represents the first step of the commonly accepted 
two-hit-hypothesis of non-alcoholic steatohepatitis. The second step in this 
explanation model is the development of an inflammatory steatohepatitis. The two 
main pathways in the pathogenesis of steatohepatitis is the effect of oxidative-stress 
induced lipid peroxidation and  cytokine mediated injury (Stewart 2001).  
 
Reactive oxygen species (ROS) are built as a by-product of the respiratory chain. In 
this energy producing metabolic pathway electrons are transported to different 
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enzyme complexes to finally reduce molecular oxygen to H2O. ROS are built if a 
small fraction of these transported electrons erroneously react with oxygen to 
reactive oxygen species. Normally, these highly active metabolites are neutralized by 
enzymatic or non-enzymatic anti-oxidants. Increased !-oxidation leads to high input 
of electrons to the respiratory chain, by this to high ROS-formation, and 
consequently, to a high consumption of anti-oxidants. A state in which ROS-
formation exceeds the cellular repair- and detoxification leads to injury of cellular and 
extracellular macromolecules. This state is called oxidative stress (Schmidt 2007). 
A possible explanation for the increased building of ROS is the decreased activity of 
respiratory chain complexes (Pérez-Carreras 2003). Both mechanisms, the 
increased input of electrons by up-regulated !-oxidation and the impaired outflow of 
electrons by lower enzyme activity lead to accumulation of electrons within the 
respiratory chain and thus, to increased ROS formation (Pessayre 2004). 
A second source of mitochondrial ROS could be hepatic CYP2E1, which is increased 
in patients with NASH. CYP2E1 can produce ROS and trigger lipid peroxidation 
(Chalasani 2003). CYP2E1 is responsible for microsomal #1- and #2-oxidation of 
free fatty acids, which leads to formation of cytotoxic decarboxylated acids and of 
free radicals (Woodcroft 2002). If the formation of ROS and free radicals exceeds 
their enzymatic and non-enzymatic metabolism, mitochondrial DNA, mitochondrial 
enzymes and proteins of the respiratory chain are damaged.  
 
Lipid peroxidation means a chain reaction mechanism that is initiated by the reaction 
of ROS and fatty acids which are commonly found in lipid membranes. Fatty acid 
radicals, very instable products of this reaction, react spontaneously with oxygen to 
form again other organic oxygen radicals. Most important representatives of lipid 
peroxidation products are malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE). If 
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this organic oxygen radical chain reaction can not be stopped by antioxidants like 
vitamin E, they cause structural and functional modifications of lipid double layers 
and biomembranes by interaction with their unsattured lipids. This leads to an vicious 
circle because by affecting mitochondrial biomembranes and with it mitochondrial 
respiratory chain, even more ROS are built. This again leads to oxidative stress and 
mitochondrial and cellular damage. Sanyal et al. could show that NASH patients 
show high levels of lipid peroxidation (Sanyal 2001). On the other side, glutathione 
levels, which serve as a marker of an organism's antioxidant capacity, are decreased 
(Vendemiale 2001). 
 
Firstly, ROS can directly damage mtDNA, respiratory chain polypeptides and 
mitochondrial cardiolipin, the latter effect relases reactive lipid peroxidation products, 
which also damage mitochondria. These effects further block the flow of electrons 
within the respiratory chain and with it increase again ROS formation. 
 
Secondly, ROS activate NF-$B, which induces the hepatic synthesis of TNF-", which 
also damages mitochondria and increases again ROS formation by increasing the 
outer mitochondrial membrane permeability for cytochrome c and thus to again 
impaired electron flow within the respiratory chain (Chalasani 2003). Crespo et al. 
could show that patients with NASH have high hepatic TNF-" mRNA levels (Crespo 
2001). 
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As a result, the production of ATP (adenosinetriphosphate), the main intracellular 
energy storage, is decreased. The impaired energy homeostasis contributes to cell 
damage (Sanyal 2001).  
 
Thirdly, high production of ROS lead to a consumption of anti-oxidants which further 
aggravates ROS-induced damages. Indeed low vitamin E levels are found in obese 
children with steatohepatitis (Strauss 1999). 
 
Both, lipid peroxidation products and TNF-" may damage mitochondria and lead to 
mitochondrial dysfunction by different mechanisms.  The hepatic mitochondria of 
NASH patients exhibit ultrastructural lesions with the presence of para-crystalline 
inclusions in megamitochondria (Caldwell 1999).  
 
Mitochondria have their own mitochondrial DNA (mtDNA). This DNA encodes for 13 
polypeptides of mitochondrial respiratory chain. Haque et al. could show that mtDNA  
is severly depleted in NASH patients (Haque 2002). Although the exact mechanism 
is still not exactly clarified, a possible explanation for this depletion could be due to 
lipid peroxidation products and ROS, which both can damage mtDNA (Hruszkewycz 
1988).  
 
TNF-" also impairs the respiratory chain by partially blocking the electron flow. TNF-
" increases the permeability of mitochondrial membranes and by this releases 
cytochrome c from the intermembrane space of the mitochondria into the cytosol. 
This partially blocks the cytochrome c mediated electron flow from complex III to 
complex for of the mitochondrial respiratory chain (Pessayre 2004). Indeed, patients 
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with NASH have an impaired in-vivo ability to re-synthesize ATP after a fructose 
challenge (fructose transiently depletes hepatic ATP) (Cortez-Pinto 1999). 
 
The cellular damage and oxidative stress cause an inflammatory reaction mediated 
by cytokines like TNF-", Interleukin-8 (IL-8) and Interleukin-6 (IL-6). The expression 
of these cytokines is mediated by ROS themselves and by activated aldehydes like 
4-HNE (Pessayre 2001). IL-8 as chemoattractant mediates immigration of leukocytes. 
As one third of the proinflammatory and leukocyte attracting Interleukin-6  is built in 
adipose tissue the correlation of obesity an steatohepatitis can be comprehended. 
This might be a reason why obesity also favors the transition from steatosis to 
steatohepatitis. 
 
Another source of cytokine production is the activation of resident hepatic 
macrophages called Kupffer cells. Kupffer cells are activated by endotoxines that 
reach the liver from the intestine via the portal vein. Endotoxins are structural 
molecules of the outer bacterial membrane. Prototypical examples of endotoxin are 
lipopolysaccharide (LPS) and lipooligosaccharide (LOS). High intestinal endotoxin 
production is the result of bacterial overgrowth, a state which is associated with 
NASH (Wigg 2001). Endotoxins activate the Toll-like-receptor 4 (TLR-4) and CD14, 
both endotoxine receptors on the cell surface of Kupffer cells. This activates the 
transcription of  pro-inflammatory cytokines, like TNF-" or IL-6 (Michael 2004).  
Cytokines induce the immigration of leukocytes out of the blood vessels and are 
capable of producing all of the classical histological features of NASH (see below).  
 
As already discussed, there are different sources of TNF-". It can be released by fat-
engorged adipocytes, by ROS-stimulated hepatocytes or by endotoxin-stimulated 
  Page 11 of 65 
 
Kupffer-cells. TNF-" interacts with its receptor TNF-receptor 1 (TNFR1). The hepatic 
expression of both, TNF-" mRNA and TNFR1 is increased in patients with NASH 
(Crespo 2001). This interaction of TNF-" and TNFR1 activates a apoptotic pathway 
by activating a casade of proteases (caspases), which make the outer mitochondrial 
membrane leaky for proteins (cytochrome). Further mitochondrial damage also 
opens the inner mitochondrial membrane for proteins which exaggerates apoptosis. 
Caspase levels are also increased in patients with NASH or alcoholic liver disease 
(Ramalho 2006). 
 
A second pathway to initiate a apoptose pathway is the interaction of Fas, a 
membrane receptor, with its ligand, the Fas ligand. Normally, hepatocytes express 
Fas, but not Fas ligand, which prevents the from killing their neighbour hepatocytes. 
Similar to TNFR1, Fas expression is also increased in NASH patients (Feldstein 
2003). Above described conditions in hepatocytes leading to increased ROS 
formation can cause Fas ligand expression by hepatocytes, so that Fas ligand on 
one hepatocyte can now interact with Fas on another hepatocyte, to cause its 
apoptosis (Pessayre 2000).  
 
A major drop of hepatocellular ATP levels prevents apoptosis, which requires energy, 
and blocks plasma membrane pumps. This causes cell and organelle swelling 
(ballooning) and later plasma membrane rupture and necrotic cell death 
(necroinflammation) (Leist 1997). Hepatocellular ballooning (see below) refers to 
enlarged hepatocytes with rarefied, reticular cytoplasm indicating cell injury. It is 
considered as the result of alterations in intermediary filament cytoskeleton (Tiniakos 
2010).  
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Kupffer cells, which ingest apoptotic bodies, release TGF-!, which activates hepatic 
stellate cells (Ito-cells) into collagen-producing myofibroblastic cells. Cytokines and 4-
hydroxynonenal (4-HNE) and malondialdehyde (MDA) also induce liver fibrosis via 
activation of stellate cells and result in increased production of transforming growth 
factor-beta (TGF-!). Leptin, another member of the adipokine family, which is – in 
contrast to adiponectin – up-regulated in NASH patients contributes to insulin 
resistance and might even stimulate fibrogenesis in animal models of NAFLD 
(Ikejima 2001).  
 
Lipid peroxidation products activate fibrogenesis in two ways: Firstly, lipid 
peroxidation products enhance the production of TGF-! by macrophages 
(Leonarduzzi 1997). Second, lipid peroxidation products directly induce collagen 
production by activated stellate cells (Parola 1993).  
 
TGF-! also induces tissue transglutaminase. This enzyme is associated with the 
cytoskeleton, including intermediary filaments. The induction of tissue 
transglutaminase could partizipate in the generation of Mallory bodies, which are 
formed of aggregated cytoskeletal proteins, in particular polymerized cytokeratins 
(Pessayre 2001). 
 
Histology 
Non-alcoholic fatty liver disease 
The minimal histological change of NAFLD is hepatocellular steatosis which means 
accumulation of triglycerides within spezial liver tissue cells called hepatocytes. This 
hepatocellular steatosis is present in all cases and has generally benign course.  
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According to the American Association fort the study of liver diseases (AASLD) 
NAFLD is defined as the accumulation of fat in the liver tissue exceeding 5 to 10%  
by weight (Neuschwander-Tetri 2003).  
 
This steatosis is commonly macrovesicular, that means a singular large fat droplet or 
smaller well-defined intracytoplasmatic doplets displacing the nucleus. Rarely, 
groups of hepatocytes with microvesicular steatosis may also be found. In this case, 
these hepatocytes are filled with many tiny lipid droplets that do not displace the 
nucleus (Tiniakos 2010). Figures 3 and 4 are supposed to show this difference 
between macro- and microvesicular steatosis. 
 
Fig.3: Nonalcoholic fatty liver disease: microvesicular steatosis  
in most hepatocytes, while one shows macrovesicular steatosis  
(arrow) (hematoxylin and eosin, _400). 
Source: Tiniakos 2010 
 
Non-alcoholic steatohepatitis 
The histological finding of NASH is often a trias of steatosis which was described 
above, hepatocellular balloning and lobular inflammation. This trias represents the 
minimal criteria for adult NASH. In 10-15% of NASH patients progressive fibrosis can 
also be found, but just like in other chronic liver diseases, fibrosis is not required for 
the diagnosis of steatohepatitis. However, there are no histological differences 
between alcohol induced and non-alcoholic fatty liver diseases. 
Fig. 4: Nonalcoholic fatty liver disease: macrovesicular 
steatosis (hematoxylin and eosin, _100). 
Source: Tiniakos 2010 
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Hepatocellular ballooning means enlarged hepatocytes with rarefied, reticular 
cytoplasm indicating cell injury. It is considered as the result of alterations in 
intermediate filament cytoskeleton. Other forms of hepatocellular injury like apoptotic 
bodies and lytic necrosis may also 
be present (Tinakos 2010). Loss of 
keratin 8/ 18 immunostaining might 
be a possible marker for 
intermediate filament alterations 
(see Figure 5). 
 
 
 
 
Inflammation is a possible feature of NASH histology. If present it is usually mild and 
consists of mixed inflammatory cell infiltrate. “Satellitosis”, a lesion often seen in 
NASH histologies, means polymorphs around ballooned hepatocytes. Inflammation 
can be observed in lobular and portal areas. In untreated patients, portal 
inflammation can be considered as a marker of advanced disease, as it correlates 
with a diagnosis of definite steatohepatitis and advanced fibrosis (Tiniakos 2010). 
 
Fibrosis in patients with non-cirrhotic NASH is typically perisinusoidal/ pericellular 
(chickenwire). Fibrosis is associated with active lesions of NASH but may also be 
seen without. With progression of NASH, portal and periportal fibrosis may be 
observed, in some cases by bridging fibrosis (Tiniakos 2010).  
 
Fig. 5: Nonalcoholic steatohepatitis: immunohistochemistry for 
Keratin 18, highlights absence of staining in ballooned hepatocytes 
(arrows) and positive staining in Mallory–Denk bodies 
(arrowheads), _400. 
Source: Tiniakos 2010 
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Mallory-Denk bodies - another histological feature that can be found in NASH - are 
irregularly shaped, eosinophilic, 
intracytoplasmatic inclusions composed of 
keratins 8 and 18, ubiquitin, heat shock 
proteins and p62. Mallory-Denk bodies are 
usually found in ballooned hepatocytes 
(see Figure 6) (Zatloukal 2004).  
 
 
Megamitochondria (see etiology) appear in the histological image as round 
eosinophilic structures within hepatocytes and (as discussed above) are a result of 
lipid peroxidation. On electron microscopy, these abnormal mitochondria show 
paracrystalline and loss of cristae (Sanyal 2001, Caldwell 2004). 
 
Glycogenated nuclei are vacuolated nuclei and are typically located in periportal 
hepatocytes (Sorrentino 2004). Some investigators consider them as characteristic 
for NASH because they are found very rarely in biopsies of alcoholic steatohepatitis.  
 
Grading and Staging 
Matteoni et al. initially proposed a classification system that correlated features of 
NAFLD with disease outcome: they descriped four types of NAFLD: simple steatosis 
(type 1), steatosis and lobular inflammation (type 2), steatosis and hepatocellular 
ballooning (type 3), and steatosis with ballooning and either Mallory-Denk bodies or 
fibrosis (type 4). In this classification type 3 and 4 histologically and clinically 
resembled NASH as diagnosed now and were associated with subsequent 
Fig. 6: Nonalcoholic steatohepatitis: liver cell injury in 
the form of ballooning (thick arrow) and apoptotic body 
(thin arrow) is evident. The ballooned hepatocyte 
contains a Mallory–Denk body (arrowhead) (hematoxylin 
and eosin, _400). 
Source: Tiniakos 2010 
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development of cirrhosis. This system did not include assessments of disease 
severity and was intended mainly for clinical use (Matteoni 1999). 
 
Brunt et al. proposed another grading classification system based on the major 
histopathological lesions of NASH, that is steatosis, hepatocellular ballooning and 
inflammation (see Table 1). They also proposed a staging method for the 
characteristic pattern of fibrosis in NASH (see Table 2) (Brunt 1999). 
Table 1. Brunt grading system for NASH 
Grade Steatosis Ballooning Inflammation 
Mild (grade I) 1-2 Minimal L= 1-2  P= 0-1 
Moderate (grade II) 2-3 Present L= 1-2 P= 1-2 
Severe (grade III) 2-3 Marked L= 3 P= 1-2 
Steatosis:  
1: 0-33%,  
2: 33-66%  
3: 66-100% 
Lobular inflammation (L):  
0= none,  
1= < 2 foci/ 20x field,  
2= 2-4 foci/ 20x field,  
3= > 4 foci/ 20x field. 
 
Portal inflammation (P):  
0= none,  
1= mild,  
2= moderate,  
3= marked. 
(Brunt 1999) 
 
Table 2. Brunt staging system for NASH 
Stage Perisinusoidal fibrosis Periportal fibrosis Bridging fibrosis Cirrhosis 
1 Focal or extensive 0 0 0 
2 Focal or extensive Focal or extensive 0 0 
3 +/- +/- + 0 
4 +/- +/- extensive + 
(Brunt 1999) 
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1.2    Epidemiology and risk factors 
Epidemiology 
Non-alcoholic fatty liver disease has become the most common liver disease in 
Western countries. The prevalence in of NAFLD is rapidly increasing worldwide in 
parallel with the rising prevalence of obesity and type 2 - diabetes (Björnsson 2007). 
The prevalence of NAFLD is estimated to be 20-30% in adult population in 
industrialized countries. It is important to note that these numbers are always 
dependant on the method used to diagnose fatty liver, the method to assess alcohol 
consumption and the cut-off used to exclude alcoholic liver disease. The prevalence 
of NASH in common population is estimated to be 2-3% (Bellentani 2004). 
 
The prevalence of NAFLD varies according to age, gender and weight status: 
Gender 
In contrast to early studies emphasizing that NAFLD is more common in women, 
recent studies show that NAFLD may be even more prevalent among males. A 
possible reasond for this might be the postulation that female hormones protect 
against NAFLD. This postulation is supported by evidence showing that NAFLD is 
twice as common in post-menopausal women as in premenopasual women. Women 
receiving hormone replacement therapy are significantly less like to have NAFLD 
compared with women without hormone therapy (Clark 2002, Carulli 2006, McKenzie 
2006).  
 
Age 
NAFLD can be found in all age groups. However, as a rule, the prevalence appears 
to increase with age. An old study out of 1977 showed a prevalence of 1% in people 
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under 20 years, 18% in the group of 20 to 40 years and 39% in people among 60 and 
older (Hilden 1977). 
 
Type 2 Diabetes 
Several studies have described a higher prevalence of NAFLD among type 2 
diabetes patients compared with non-diabetics with prevalence estimates ranging 
from 40% to 69.5% (Targher 2007, Angelico 2005, Kelley 2003). Patients with type-2-
diabetes do not only have higher prevalence of NAFLD, but also appear to have 
more severe forms of the disease, including NASH and fibrosis (Angulo 1999, Dixon 
2001). 
 
Weight 
In their review of twelve studies on prevalence of NAFLD, Machado et al found a 
prevalence of NAFLD up to 90% in morbidly obese patients with a body mass index 
(BMI) of more than 40kg/ m% (Machado 2006). 37% of these patients undergoing 
bariatric surgery had NASH. 
 
There is very few data available on the incidence of NAFLD in the general 
population. In a 8.5-year-follow-up of the Dionysos Study a incidence of 18.5 per 
1000 person-years was found (Bedogni 2007). 
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Insulin resistance 
As described above, insulin resistance is considered to be the pathophysiological 
cause of NAFLD. Several studies have found strong associations between direct 
measures of insulin resistance and NAFLD. In addition, different studies showed a 
good correlation between NAFLD and metabolic syndrome which is considered to be 
the clinical construct of insulin resistance. A long-term prospective study 
demonstrated that the presence of metabolic syndrome is associated with increased 
odds for NAFLD (OR= 4.0 for men and 11.2 for women) (Hamaguchi 2005). Another 
cross-sectional study found that the presence of metabolic syndrome was associated 
with higher odds of NASH (OR = 3.2) and fibrosis (OR = 3.5) (Marchesini 2003). 
 
Obesity 
Worldwide, obesity remains the most important and well-described risk factor for 
NAFLD. Obesity is defined as a body mass index (BMI) greater tha 30 kg/ m%. In the 
Dionysos study, NAFLD was present in 94% of obese population, 67% in overweight 
population and 24.5% in normal weight population (Bellentani 2004). Regardless of 
BMI, patients with truncal obesity are at greater risk of fatty liver disease. 
 
Genetic factors 
A genetic susceptibility to NAFLD, NASH and its complications has been postulated. 
Environmental factors like obesity cause simple steatosis in the majority of people. 
However, in a minority of the expsed, more advanced forms of NAFLD and 
hepatocellular cancer can be found. This leads to the hypothesis that susceptibility is 
inherently determined. Epidemiologic studies showing familial aggregation of NFALD 
and insulin resistance also support a genetic basis for NAFLD. Furthermore, studies 
have found inter-ethnic-variations in the prevalence of NAFLD (Lazo 2008).  
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Other risk factors to develop NAFLD are disorders of lipid metabolism, total 
parenteral nutrition, iatrogenic medication with diltiazem, amiodarone, tamoxifen, 
steroids and highly-active anti-retroviral therapy. 
 
1.3    Metabolic syndrome: definition and components 
The metabolic syndrome is defined by the presence of 3 or more of the following 
criteria: increased waist circumference, hypertriglyceridemia, hypertension, high 
fasting glucose or a low high-density lipoprotein (HDL) level. Most NAFLD patients 
carry at least one feature of metabolic syndrome and/ or are obese. Conversely, it 
has been shown that a high number of patients with metabolic syndrome have 
steatotic livers. NAFLD is recognized to be the hepatic manifestation of the metabolic 
syndrome. 
 
1.4   Clinical manifestation and diagnosis 
Diagnosis of NAFLD is based on clinico-pathological criteria. A diagnosis of NAFLD 
can be achieved by excluding other causes of abnormal liver function tests and after 
performing appropriate imaging. Liver biopsy is still considered as the gold standard 
for the diagnosis of NAFLD. But still, in the clinical setting, there is no consensus, 
about whether or not liver biopsy is required to confirm a diagnosis of NAFLD. 
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History and physical examination 
Most NAFLD patients are asymptomatic. They are mostly identified while undergoing 
imaging examination for evaluation of abnormal liver function test results. Patients 
might complain about light right upper quadrant abdominal pain, nausea and other 
non-specific symptoms concerning the gastrointestinal tract (Lewis 2010). 
 
In the physical examination hepatomegaly is common. In patients with cirrhotic livers, 
of course, all signs of portal hypertension may occur (i.e. ascites, edema, spider 
angiomas, varices, gynecomastia). As metabolic syndrome is the most common 
association, increased waist circumference is common. 
 
Serology 
There is no single biochemical marker that can confirm a diagnosis of NAFLD or 
distinguish between steatosis, NASH and cirrhosis. Liver function test (LFT) 
abnormalities are common in NAFLD patients, with (if present) slightly elevated 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT), usually not 
exceeding four times the upper limit of normal with ALT higher then AST. A ratio of 
AST/ ALT greater then 2 suggests an alcoholic cause (Pratt 2000). In addition, some 
patients can present with isolated elevations of alkaline phosphatise (Pantsari 2006). 
 
Alkaline phosphatase levels can also be elevated in NASH patients. Hyperlipidemia, 
elevations of serum ferritin, iron and decreases of transferring saturation may also 
occur in patients with NASH. 
 
Poynard et al. proposed the SteatoTest, a battery of biochemical markers including 
ALT, "2-macroglobulin, apolipoprotein A-I, haptoglobin, total bilirubin, &-glutamyl 
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transpeptidase (GGT), cholesterol, triglycerides, glucose, age, gender, and BMI, that 
predicted >30% steatosis with sensitivity of 90%, specifity of 90%, negative predictive 
value of 93% and positive predictive value of 63% (Poynard 2005). 
 
The FibroTest, another test to diagnose advanced fibrosis in NASH by biochemical 
markers, including "2-macroglobulin, apolipoprotein A-I, haptoglobin, total bilirubin, &-
glutamyl transpeptidase (GGT) and ALT. It is useful to find predictors of fibrosis 
because patients with elevated markers of fibrosis might be at risk for developing 
cirrhosis and its complications. The positive prediction value of this test ist 73%, the 
negative predictive value for severe fibrosis is 90%, but the test does not differentiate 
among stages of fibrosis. Similarly, the NAFLD fibrosis score, an index consisting of 
age, hyperglycaemia, body mass index, platelet count, albumin ans AST/ ALT ratio, 
showed a positive prediction value of 82% and a negative predictive value of 93% 
(Ratziu 2006). 
 
Leptin, a hormone secreted by adipose tissue (as discussed above), has shown 
profibrotic effects in animal models (Ikejima 2001). Even though human studies 
reported that elevated leptin levels are found in patients with steatosis and NASH, 
absolute leptin levels have not been shown to correlate with degree of steatosis or 
fibrosis (Uygun 2000). 
 
TNF-!, another inflammatory mediator involved in the “multi-hit-hypothesis” (see 
above), is elevated in patients with NASH and absolute TNF- " correlate with severity 
of inflammation and fibrosis (Crespo 2001). Other circulating markers of 
inflammation, in particular interleukin-6 (IL-6), CC-chemokine ligand 2 (CCL-2) and 
hyaluronic acid (HA) are elevated in NASH patients (Haukeland 2006, Suzuki 2005). 
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Imaging 
Ultrasound is the main imaging procedure to detect NAFLD related liver changes. 
The ultrasound correlate of steatosis is increased echotexture, called a “bright liver”. 
The hepato-renal contrast predicts steatosis and fibrosis more accurately. Non-
steatotic hepatic parenchyma exhibits an echotexture similar to that of renal 
parenchyma. In steatotic livers, the liver parenchyma appears “brighter” because fat 
appears white in ultrasound imaging. Saadeh et al. found the sensitivity of ultrasound 
scan to be 100% (Saadeh 2002). A possible criticism of ultrasound is that it is not 
able to evaluate inflammation and fibrosis. 
 
Liver elasticity is an non-invasive measure of liver fibrosis that is performed by 
special ultrasound machines, called Fibro-Scan. When ultrasound is used, the 
ultrasound probe emits vibrations that creates a shear wave within the liver. This 
shear wave corresponds to liver stiffness (Lewis 2010, Castera 2005). Takeda found 
a good correlation of liver elasticity measured by Fibro-Scan and Brunt fibrosis score. 
Liver stiffness was significantly higher in patients with stage 3 or stage 4 fibrosis 
(Takeda 2007). Fukuzawa et al. measured liver stiffness by Fibro-Scan of biopsy 
proved NAFLD of 135 patients and showed that liver elasticity accurately predicted 
fibrosis and that Fibro-Scan was able to distinguish each of the Brunt classification 
stages (Fukuzawa 2007). 
 
CT-scan 
CT scans are also used to evaluate liver architecture. Piekarski et al. measured CT 
numbers of normal subjects. They found an average CT number of the normal liver of 
24.9 Hounsfield units (HU) and an average CT number of the spleen of 21.1 HU. In 
this study fatty livers were associated with lower CT numbers (Piekarski 1980). 
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Lee et al. studied liver-to-spleen attenuation and visual grading on non-enhanced CT 
scans of 703 liver donor candidates and compared these values with findings of liver 
biopsies. Both measures proved accurate the diagnosis of steatosis exceeding 30% 
of the liver (Lee 2007). It appears that non-contrast CT scans are more useful in 
steatosis diagnostic (Jacobs 1998). 
 
Magnetic resonance tomography (MRI) 
Magnetic resonance tomography is able to detect steatosis reliably. Fatty changes 
are assessed by differential chemical shifts between fat and water (Lewis 2010). 
Fishbein et al. found in their study good correlation between MRI, ultrasound and 
histology in NAFLD patients. In the same study, they showed that MRI detected 
lower levels of steatosis more accurately than CT scans and ultrasound (Fishbein 
2005). But MRI assessment remains a more expansive and less accessible 
technology. 
 
 
2.  Chemokines and its receptors 
2.1   Chemical properties and classification 
Chemokines are a big family of chemotactical cytokines with structural similarities in 
their secondary structure. Chemokines can be synthesized by almost every human 
cell. Their name is derived from their main function: the ability to induce directed 
chemotaxis in nearby responsive cells. Till now, more then 44 chemokines and 21 
chemokine-receptors have been described. Chemokines are small molecules with a 
weight of 8-10 kDa and 20-70% homologies in their amino acid sequence.  
Their tertiary structure is stabilized by disulfide bonds between condensated cysteine 
residues (Fernandez 2002). 
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Fig. 7: CXC-chemokines 
 
Fig. 9: CC-chemokines 
 
 
Depending on four of these invariant cysteine residues chemokines are classified into 
four subclasses: the C-, CC-, CXC- and CX3C-subfamily. In any case the first 
cysteine residue binds covalently to the third and the second cysteine residue to the 
forth.  
 
Chemokines that have one amino acid between the first 
two N-terminal cysteines are subclassified as CXC- or "-
chemokines (see Figure 7). This subfamily is further 
divided into two groups depending on another special 
amino acid sequence (i.e. motif) consisting of three amino 
acids: glutamic acid (“E” in single letter code) – leucine  
(“L” in single letter code) – arginine (“R” in single letter code) (Fernandez 2002).  
 
Chemokines showing this motif immediately before the first N-terminal cysteine are 
called ELR-positive chemokines or ELR+-chemokines (see Figure 8), those without  
this motif are called ELR-negative chemokines or ELR—-
chemokines. Both groups also show differences in 
chemoattractant functions and bind to different types of 
receptors (2). 
 
 
If the first two N-terminal cysteines are adjacent that 
means they follow each other directly in the primary 
sequence, the chemokines are called CC- or !-
chemokines (see Figure 9).  
Fig. 8: ELR+-CXC-Chemokines 
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Fig.10: CX3C-chemokines 
 
Fig. 11: C-chemokines 
 
 
This subfamily is also divided into two subgroups: CC-chemokines containing four 
cysteines are called C4-CC chemokines and chemokines with six cysteines C6-CC 
chemokines. The latter subgroup is represented by only a small number of 
chemokines, for example CCL21. 
 
Similar to the CXC- or "-subfamily, chemokines belonging to the CX3C-or &-subfamily  
have three intervening amino acids between the first two 
cysteines (see Figure 10). This subfamily - so far – is 
represented by only one member called fractalkine or 
CX3CL1.  
 
In contrast to the members of the first three subfamilies, the chemokines of a fourth  
subfamily – the C- or '-subfamily shows only two cysteine 
residues in its primary sequence (see Figure 11) 
(Fernandez 2002). This group is represented by two 
members: XCL1 or lymphotactin-" and XCL2 or 
lymphotactin-!. 
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2.2 Function and clinical relevance of Chemokines 
As already said, chemotaxis of immune competent cells is the main function of 
chemokines. As chemoattractant they guide the migration of cells. In accordance to 
their main function, two main groups of Chemokines are distinguished: pro-
inflammatory or inducible and homeostatic or constitutive chemokines. Most 
Chemokines are pro-inflammatory and are released in response to bacterial infection, 
viruses and agents that cause physical damage. Homeostatic Chemokines are 
produced continuously and are involved in surveillance of normal tissue, such as 
directing lymphocytes to lymph nodes. 
 
 
 
 
 
 
 
 
 
Leukocyte trafficking 
Cells attracted by chemokines follow a signal of increasing chemokine concentration 
towards the source of the chemokine. By this they direct lymphocytes to lymph nodes 
so they can screen for invasion of pathogens by interacting with antigen-presenting 
cells like dendritic cells.  
 
Fig. 12: Biological functions of chemokines and chemokine receptors 
Source: Schall T. Biology of the RANTES/ SIS cytokine family. Cytokine 1991 May; 3(3): 165-83. 
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Chemokines also play a central role in the process of extravasation of leukocytes. In 
the scheme of rolling, adhesion and transmigration of immune competent cells 
chemokines are involved in every step including interactions of adhesion molecules 
and the chemoattractant function of these proteins:  
 
As part of the inflammatory response, activated thrombocytes or endothelial cells 
release chemokines which serve as signal for rolling leukocytes. These leucocytes 
“crawl” along the endothelial membrane following the chemokine gradient. This 
process is called haptotaxis. In this process RANTES seems so play a crucial role. At 
the same time leukocytes up-regulate their integrine expression on their outer cell 
membrane and endothelial cells express P-selectines, the corresponding ligand for 
integrines. This forms the basis for extravasation of leukocytes. Chemokine induced 
matrix-metalloproteases cause lysis of the basal membrane which eases the 
transmigration. 
 
Angiogenesis and angiostasis 
Angiogenesis is a biological process through which blood vessels are generated. 
Angiogenesis is not only physiological in wound healing, it is also associated with 
several chronic inflammatory diseases, such as psoriasis, rheumatoid arthritis as well 
as tumor growth and metastasis (Arenberg 1997). It is well established that ELR+-
CXC-chemokines are potent angiogenic factors, able to stimulate endothelial cell 
chemotaxis, whereas most non-ELR-CXC-chemokines are strong angiostatic factors 
which inihibit the endothelial cell chemotaxis (Strieter 1995). 
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Metastasis 
Besides their role in angiogenesis chemokines also seem to be involved in the 
process of tumor cell migration, invasion and metastasis. It is known that certain 
tumors exhibit patterns of metastasis to certain organs, in other words tumor cells do 
not migrate randomly. One possible explanation for this is that this specific migration 
of tumor cells may be determined by the Chemokine receptors they express and the 
chemokines expressed by target organs. As a proof for this hypothesis, Youngs et al 
have reported that different breast carcinoma cell lines respond differentially to 
distinct chemokines (Youngs 1997). 
 
Anti-tumor activity 
Although the presence of chemokines in some chronic inflammatory diseases may 
not be beneficial, in other diseases, like cancer, it is desirable that the immune 
response is promoted. In theory, any chemokine that is capable of inducing the 
migration of T-cells, natural killer cells (NK-cells), dendritic cells or macrophages 
could promote regression or even eradication of a tumor mass by boosting the 
immune response against the tumor. In a mouse model, lymphotactin (XCL1) in 
combination with Interleukin-2 (IL-2) has shown anti-tumor activity. The most likely 
explanation for this is, that lymphotactin induces T-cell and natural-killer cell 
infiltration to the tumor site while IL-2 expands the T-cell clones and enhances a 
specific immune response (Hedrick 1997). 
 
Organogenesis 
Although traditionally associated with the development and response of the immune 
system chemokines also play an important role in organogenesis: knock-out mice 
leaking genes for CXCL12 (SDF-") or its receptor CXCR4 have suffer from impaired 
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fetal development of the cerebellum, the cardiac septum, gastric vasculature and B-
cell lymphopoesis. These mice die either in utero or at birth (Nagasawa 1996, Zou 
1998).
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2.3   Structure and ligands of chemokine receptors 
Approximately 20 signalling chemokine receptors and 3 non-signalling Chemokine 
receptors have been reported. All Chemokine known receptors are seven-
transmembrane receptors (7TM) with seven helical membrane-spanning regions that 
are connected by extra-membranous loops. The N-terminus of the amino acid chain 
and three extracellular loops are 
exposed outside of the cell, the 
C-terminus of the amino acid 
chain and again three 
extracellular loops face to the 
intracellular loop (Allen 2007). 
Figure 13 is a good scheme to 
clarify the structure of a 7TM-
receptor. 
 
Table 7 shows a good overview of known Chemokine receptors and their chemokine 
ligands and illustrates again the fact that different ligands bind the same receptor and 
some ligands bind different receptors. 
Fig. 13: Structure of a 7TM-chemokine receptor. 
Source: Wikipedia, the free encyclopedia 
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Table 7: Chemokine receptors and their ligands 
Receptor Ligands 
CCR-1 CCL3, CCL5, CCL7, CCL13, CCL14, CCL15, CCL16, CCL23 
CCR-2 CCL2, CCL7, CCL8, CCL13, CCL16 
CCR-3 CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL16, CCL24, CCL26, CCL28 
CCR-4 CCL17, CCL22 
CCR-5 CCL3, CCL4, CCL5, CCL8, CCL11, CCL14, CCL16 
CCR-6 CCL20 
CCR-7 CCL19, CCL21 
CCR-8 CCL1 
CCR-9 CCL25 
CCR-10 CCL27, CCL28 
CXCR-1 CXCL6, CXCL7, CXCL8 
CXCR-2 CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 
CXCR-3A CXCL9, CXCL10, CXCL11 
CXCR-3B CXCL4, CXCL9, CXCL10, CXCL11 
CXCR-4 CXCL12 
CXCR-5 CXCL13 
CXCR-6 CXCL16 
CXCR-7 CXCL12 
XCR-1 XCL1, XCL2 
CX3CR-1 CX3CL1 
CCX-CKR CCL19, CCL21, CCL25 
D6 CCL2, CCL31, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL17, CCL22 
CCL22 DARC/ Duffy CCL2, CCL7, CCL8, CCL11, CCL13, CCL14, CCL16, CCL17, CXCL1, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL11, CXCL13 
 
.  
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2.4   Signalling pathways of chemokine receptors 
Activation 
Chemokine receptors are G-protein coupled receptors (GPCR). This name is derived 
from their signal transduction mechanism. A heterotrimeric G-Protein is bound to the 
intracellular loops of the 7TM-receptor (see Figure 14a). The heterotrimeric G-protein 
consists of three subunits: G"-, G!- and G&-subunit. The G"-subunit directly 
interacts with the intracellular 
loops and with the G!-subunit 
which in turn forms a tight 
complex with the G&-subunit.  
 
The G"-subunit contains a 
GTPase domain which is 
involved in binding and 
hydrolysis of GTP (=guanosin triphosphate). In the inactive state, the G"-subunit 
binds GDP (=guanosin diphosphate) (see Figure 14a).! 
 
When a ligand binds to the 
GPCR receptor, the receptor 
itself changes its conformation 
and by this activates the 
intracellular G-Protein causing 
dissociation of GDP from the 
G"-subunit and its 
replacement by GTP.  
Fig. 14a: Signalling pathway of chemokine receptors 
 
Fig. 14b: Signalling pathway of chemokine receptors 
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The G"-subunit then dissociates from the receptor and from the G!&-heterodimer 
(see Figure 14c-e). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14c: Signalling pathway of chemokine receptors 
Fig. 14d: Signalling pathway of chemokine receptors 
Fig. 14e: Signalling pathway of chemokine receptors 
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Both complexes, the G"-GTP-complex as well as the G!&-heterodimer-complex, 
then activate downstream 
effectors with different 
physiological responses: The 
G!-subunit activates an 
enzyme called 
Phospholipase C (PLC) 
which is part of the cell 
membrane. PLC cleaves 
Phosphatidylinositol(4,5)-bisphosphate (PIP2) to form two second messenger 
molecules called inositol-triphosphate (IP3) and diacylglycerol (DAG). As second 
messenger DAG activates 
protein kinase C, IP3 
triggers the release of 
calcium from intracellular 
stores, for example the 
sarcoplasmatic reticulum. 
These effects promote 
different cascades effecting 
different cellular responses. 
 
The G"-.subunit directly activates an enzyme called protein tyrosine kinase (PTK) 
which phosphorylates serine and threonine residues in the tail of the chemokine 
receptor causing its desentisation or inactivation (see Figure 14g) (Murdoch 1995). 
 
 
Fig. 14f: Signalling pathway of chemokine receptors 
 
Fig. 14g: Signalling pathway of chemokine receptors 
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The G"-GTP-complex is hydrolysated into a G"-GDP-complex with fewer intrinsic 
energy. This complex then binds the G!&-complex and as new-formed heterotrimeric 
complex to the GPCR receptor. By this the GPC-receptor is regenerated. 
 
 
 
 
 
 
 
 
 
 
Fig. 14h: Signalling pathway of chemokine receptors 
 
Fig. 14i: Signalling pathway of chemokine receptors 
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Inactivation 
The GPCR is inactivated by agonist-dependent phosphorylation of the C-Terminus of 
the amino acid chain. Receptor phosphorylation subsequently promotes binding of 
arrestins which blocks further interaction with G-proteins and mediates receptor 
internalization through clathrin-coated pits. Receptor phosphorylation is consequence 
of continued stimuli by corresponding ligands. 
 
3.   RANTES/ CCL-5-Chemokin 
Chemokine (C-C motif) ligand 5 (CCL5) is also known as Regulated upon Activation, 
Normal T-cell Expressed and Secreted (RANTES). With its two pairs of adjacent 
cysteine residues it belongs to the CC-chemokine subfamily. It was originally 
identified by Schall et. al. via subtractive hybridisation, a screening technology based 
on PCR reaction to identify differentially  expressed genes (Schall 1988, Diatchenko 
1996). RANTES is also called SIS-delta, SCYA5, EoCP-1 (eosinophil chemotactic 
polypeptide) or TCP228 (T-cell-specific-protein). 
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3.1  Coding Gene, structure and synthesis 
The coding gene for RANTES has been shown to be located on Chromosome 17, 
position 17q11.2-q12 (Donlon 2006).  
 
In its primary structure, RANTES shows a cleaved signal peptide consisting of about 
20 to 24 amino acids and a mature secreted protein of 68 to 76 amino acids. The 
RANTES protein is a highly 
basic polypeptide with a 
molecular weight of 8kDa. 
Figure 15 shows the complete 
primary structure of RANTES, 
Figure 16 its tertiary structure 
(Schall 1991). A large amount of 
basic residues in the amino acid 
chain renders it a highly basic  polypeptide. This might be a possible explanation for 
the ability of RANTES to bind negatively charged endothelial cells of blood vessels 
(Krensky 1995).  
 
 
Fig. 15: Primary structure of RANTES 
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As already said, RANTES belongs to the CC-subfamily of chemokines with the first 
two N-terminal cysteine residues adjacent to each other. 
 
The RANTES gene structure exhibits a three exon/ two intron strucuture. The first 
exon contains the 5’ untranslated sequence and coding nucleotides for the leager 
peptide, the second exon encodes the N-terminal half of the mature protein. The third 
exon consists of carboxyl-region-coding nucleotides and the 3’ untranslated region 
(Schall 1991). 
 
The RANTES monomer structure is similar to the structure of Interleukin-8 and MIP-
1". But in their quartery structure RANTES and MIP-1" differ from Interleukin-8. 
RANTES dimers are elongated and cylindrical with dimension of approximately 66 by 
37 angstroms (Krensky 1995). 
 
Fig. 16: Tertiary structure of RANTES 
Source: Created by Nevit Dilmen, from PDB with Cn3D, http://www.ncbi.nlm.nih.gov/Structure/ 
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Before releasing RANTES undergoes different post-translational modifications like O-
glykolisation of the serine-residues or oxygenation of the methionine residue.  
 
 
3.2   RANTES expression and its regulation 
RANTES is a proinfammatory cytokine and is normally not expressed by most 
tissues. Although RANTES was originally indentified in activated T lymphocytes, 
different cell types are able to express this cytokine upon stimulation. These cell 
types include renal tubular epithelialium and mesangium, synovial fibroblasts, 
endothelial cells, platelets, monocytes, T lymphocates and dendritic cells, natural 
killer cells. 
 
It was found that RANTES was significantly upregulated upon stimulation with TNF-", 
CD40L, LPS and PMA (Zhou 1995, Sallusto 1999). 
 
The infiltration of mononuclear cells, on of the hallmarks of organ transplant rejection, 
may be mediated by expression of RANTES, in part at least. Also inflamed tissue, 
like infected tonsils has been shown to express RANTES. Also in extramedullar 
hematopoesis, a clinical situation where blood forming cells are found in the spleen, 
high RANTES expression in megakaryocytes can be seen. Megakaryocytes are 
capable of platelets production. RANTES expression can also be found in lymph 
nodes showing delayed type hypersensitivity lesions (DTH) found in sarcoidosis and 
tuberculosis.  
 
RANTES is not only expressed by inflammatory tissue, but also by transformed 
tissue. RANTES mRNA is expressed by solid tumor cell lines such as 
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rhabdomyosarcoma, RD and osteosarcoma cells for examples. The observation that 
RANTES is expressed in relatively undifferentiated tumor tissues, like in Wilms` 
tumor and generally not expressed in relatively differentiated  cell types, which make 
up the renal cell carcinomas and also that RANTES is expressed by tumors but not 
by normal tissue leads to the suggestion that RANTES expression may be 
developmentally regulated. 
 
While most of the RANTES/ SIS cytokine family are massively inducible in 
hematopoietic cells, RANTES is not rapidly induced in hematopoietic cells (Schall 
1991). RANTES expression in T lymphocytes is regulated by Kruppel like factor 13 
(KLF13) (Song 2010). 
 
3.3    In-vivo effects and associated diseases 
Inflammatory activities 
The migration of neutrophils and mononuclear phagocytes is a hallmark of 
inflammation. Once at the inflamed site, these cells are activated to destroy 
microorganisms and cellular debris, remove injured and degraded endogenous 
tissues and mount an immune response. The complex cascade of inflammatory 
events is mediated through various cells near the inflamed site, which are in turn 
attracted to that site by various chemotactic substances including bacterial 
membrane components, complement protein fragments and lymphokines.  
 
To appreciate the significance of RANTES and other chemokines one must 
understand the broader context of leukocyte/endothelial interaction. Leukocyte 
migration from the circulation into tissue involves a series of interactions between 
molecules on the surface of a leukocyte and the endothelial surface. Within the 
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scheme of “rolling, adhesion and transmigration” of leukocytes chemokines play a 
central role as they interfere on nearly all steps of the extravasation process of 
immune competent cells: In sites of inflammation activated thrombocytes and 
endothelial cells release and present cytokines which act as signal for rolling 
leukocytes (Springer 1995). 
 
In the first step, a leukocyte loosely binds to the endothelium via members of the 
selectin family. This loose tethering slows the rate of leukocyte passage through the 
vessel and allows cells interaction with chemoattractant molecules (such as 
RANTES) which are displayed on the endothelium. In the second step, the 
chemokines induce upregulation of integrins on the surface of leukocytes. This leads 
to the third step whereby the integrins on the surface of leukocytes bind their ligands 
on endothelium, i.e. selectins, which induces a firm adhesion and resulting in arrest 
of the rolling leukocyte.  
 
In the fourth step, leukocytes then cross the endothelial lining of the blood vessel to 
enter the tissue: Matrix-metalloproteases which are up-regulated by chemokines 
ease the transmigration of leukocytes by lysis of the basal membrane. After 
extravasation the leukocytes then follow a soluble chemokine gradient to sites of the 
highest chemokine concentration. This process is called haptotaxis (Rot 1993). In 
this process RANTES seems to play a decisive role (Weber 2001). 
 
RANTES plays an active role in recruiting leukocytes into inflammatory sites. 
RANTES induces leukocyte migration by binding specific receptors CCR1, CCR3, 
CCR4 and CCR5 (see above). With the help of particular cytokines like Interleukin-2 
(IL-2) and Interferon-& (IFN- &) released by T cells, RANTES also induces the 
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proliferation and activation of certain natural-killer (NK) cells to form CHAK (CC-
Chemokine-activated killer) cells (Maghazachi 1996) . 
 
Although RANTES was initially considered to be T cell-specific it has since been 
found to have a high chemotactic activity towards multiple immune cells like 
eosinophils, basophils, mast cells, monocytes, cytotoxic T cells (CTLs), naïve CD4+ 
T cells. These cells express some of the CCL5 receptors like CCR1, CCR3, CCR4, 
CCR5 (Lapteva 2010). It has also been shown to attract monocytes as well as very 
specific T cell subsets, but not neutrophils (Schall 1990). 
 
It causes the release of histamine from basophils and activates eosinophils. This 
cytokine is one the major HIV-suppressive factors produced by CD8+ cells (Rot 
1992). 
 
It can also be involved in direct antimicrobial (anti-trypanosomal) activity by inducing 
NO in macrophages (Villalta 1998). 
 
However, RANTES can have detrimental effects via the recruitment of immune cells 
that enhance inflammatory processes such as arthritis, atopic dermatitis, nephritis, 
colitis, and other disorders (e.g., arteriosclerosis, pulmonary hypertension, asthma, 
nasal polyps, endometriosis, nephropathy, and perhaps Alzheimer’s disease). High 
levels of RANTES can also be found in allogenic transplant rejection (Appay 2001). 
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RANTES levels with alcohol-induced hepatitis 
Berres et al. could show that RANTES plays a pro-fibrotic role in human and murine 
liver fibrosis. In human HCV infected livers, RANTES mRNA expression was 
significantly associated with higher stages of liver fibrosis and NASH.?Genetic 
deletion of RANTES in fibrosis prone mice led to a significantly reduced degree of 
fibrosis as assessed by liver histology and hydroxyproline content in both murine 
models of fibrosis (Berres 2008). 
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II. PATIENTS AND METHODS 
1. Patients 
1.1 Patient recruitment 
The collection of patients’ data started in February 2009. Originally, data of 506 
randomly selected fasting patients from different Departments of the University 
Hospital Regensburg was collected and included in this study. Non-fasting patients 
did not take part in this study examination. The cohort consisted of both outdoor 
patients and hospitalized patients who were referred to the interdisciplinary 
ultrasound department for sonographic examination of the abdomen. 
 
All patients took part in a face-to-face interview. The interview was carried out by one 
of three students from the Department of Inner Medicine of the University Hospital 
Regensburg. For these interviews a standard questionnaire (see figure 18) was built 
and provided including a short history of patients’ medical history (see below). 
 
1.2 Exclusion criteria 
Patients with any of the following criteria were excluded from the study:  
1. History of malignancies of any kind 
2. Chronic hepatobiliary diseases 
3. Ascites 
4. Medications known to affect hepatic steatosis  
(as estrogens, corticosteroids, amiodarone, valproate either at present or 
within the last 2 years),  
5. Inflammatory bowel disease,  
6. Infection with the human immunodeficiency virus (HIV),  
7. Chronic drug or alcohol abuse (more than 20 g/day),  
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8. Known (familial) hyperlipidemia, and  
9. Acute medical conditions with confounding effect on laboratory measurements 
and RANTES serum levels. 
 
After exclusion of all patients who did not meet our requirements the remaining study 
population consisted of 155 patients. 
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Fig. 17: Questionnare of this study about epidemiologic data and medical history of the 
patient (diseases, medication, family history, diabetes, liver diseases, malignant or 
metabolic diseases, usage of alcohol, nicotin and drugs, blodd transfusions) 
 
2. Methods 
2.1 Questionnaire 
The questionnaire also included patient information and epidemiological data as sex, 
date of birth, nationality and treatment (ambulant or hospitalized). The patients’ 
medical history included questions about the reasons for the actual hospitalisation or 
ambulant referral to the ultrasound department, the past medical history, actual 
medication, and diseases known in his family and particular questions related to a 
known diabetes, liver diseases, problems with the lipid metabolism or a known 
cancer disease and other questions like history of blood transfusions. 
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The patients were also asked about their daily alcohol consumption and their nicotine 
consumption. The daily consumption of alcohol was mainly answered in “bottles of 
beer per day” or “glasses of wine per day” and then converted in “mg of ethanol per 
day”. Furthermore, the patient was asked about any history of drug consumptions. 
Figure 17 shows the original questionnaire that was used in this study. 
 
 
2.2 Anthropometric measurements and clinical examination 
After signing the consent form and the finishing interview using the above printed 
standard questionnaire (see Fig. 18), each patient underwent a general physical 
examination.  
 
Height and weight 
The height of the standing patient was measured using a fixed scale on the wall in 
centimeters. The weight of each patient was measured using the same scale. The 
patients were asked to undress except for thin clothes with their shoes off. 
 
Blood pressure and heart rate 
Blood pressure and heart rate of a seating patient were measured on the right and 
left upper arm, the same level as the patients’ heart. The blood pressure cuff had 
been adjusted to the circumference of the upper arm. Before the blood pressure was 
measured, the patient had to rest for at least 5 minutes, and during the measurement 
the patient was asked not to talk. The heart rate was detected by palpation of the 
patient’s right radial artery and counting the puls waves for 15 seconds. The result 
was multiplied by 4 to get the heart rate per minute. 
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Waist and hip circumference 
The waist and hip circumference was measured on the standing patient using a 
flexible measuring band. The patients waist circumference was measured at the 
smallest level of the torso during minimal inspiration. The hip circumference was 
taken at the largest circumference between the edge of the iliac bone and the upper 
part of the thigh bone, at the level of the anterior superior iliac spine. Figure 18 shows 
the form that was used for documentation of anthropometric measurement and 
clinical examination. 
 
 
Fig. 18: Documentation of physical examination (weight, heigt, hip and waist circumference, blood 
pressure and heart rate) !
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Collection and storage of serum samples 
For the collection of patients serum blood was taken either from the right or the left 
upper arm of the patient. After a close skin disinfection with alcohol swabs and 
venous congestion by using a tourniquet around the upper arm blood samples were 
taken from each patient mostly out of the cubital vein: one red EDTA tube of 5ml and 
one white serum tube of 7.5 ml. 
 
The plasma was obtained by centrifugation of the serum tube at 3,000 rpm  for 10 
minutes. The plasma then was stored in aliquots at minus -20° Celsius for 
subsequent analysis.  
 
2.3 Biochemical analysis of serum parameters 
The following laboratory analyses were performed by the same laboratory, the 
certified Institute for Clinical Chemistry and Laboratory Medicine of the University 
Hospital Regensburg:  
• Aspartate aminotransferase (AST),  
• Alanine aminotransferase (ALT),  
• Gamma-glutamyl-transferase (&-GT);  
• Triglycerides,  
• Very-low-density lipoprotein cholesterol (VLDL-C),  
• Low-density lipoprotein cholesterol (LDL-C),  
• High-density lipoprotein cholesterol (HDL-C) and  
• Total cholesterol;  
• Albumin,  
• Total serum protein,  
• Bilirubin,  
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• Choline esterase,  
• Akaline phosphatase (ALP) and  
• Glucose.  
 
2.4 Ultrasound examination of the liver and fat tissue 
In addition to a complete abdominal ultrasound examination all patients underwent a 
standardized ultrasound examination performed by the same three investigators 
(Hanna Huber, Catrin Beer and Christoph Nießen).  
 
For this assessment the following high-end ultrasound machines were used: 
• Siemens Sonoline Elegra (Siemens, Erlangen, Germany) 
• Siemens ACUSON Sequoia 512 (Siemens, Erlangen, Germany), 
• GE Healthcare Logic 9 (GE Medical Systems, Wisconsin, USA) or  
• Hitachi EUB-8500 (Hitachi Medical Corporation, Tokyo, Japan). 
 
Ultrasound examination of liver 
For the ultrasound assessment of the liver the patients were asked to lie on their 
back with their arms folded behind their heads. All results of the ultrasound 
assessment were written down on a standard form for the study’s ultrasound 
examination (see Figure 19). In addition, ultrasound pictures of each measurement 
were printed for documentation. 
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The liver was examined in transverse and longitudinal section planes using a 3.5 
MHz transducer with the patient lying on his back. For the longitudinal scan the 
transducer was put on the epigastric angle, left to the midline in the hypochondrium 
in longitudinal direction. From there, the transducer was moved slowly to the right 
costal margin and right posterior axilla line. With these longitudinal planes it is 
possible to analyse size (longitudinal size measured in the medioclavicular line), 
shape, internal structure and compressibility of the left and right lobes. To 
Fig. 19: Ultrasound examination form used in this study. Liver size measured in medioclavicular line, 
ascites, echogenity of the liver, liver structure, liver masses, thickness of the fat layer over the right costal 
arch and periumbilical, liver surface, incompressibility and maximum flow in the portal vein. !
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optimise the view of the liver, compliant patients can be asked to suspend in deep 
inspiration during short periods. At the same time it is possible to get an impression 
of the gall bladder, hepatic porta, portal vein, inferior vena cava and common hepatic 
duct.  
 
Transverse scans can be useful for analysis of the left lobe of the liver, the hepatic 
porta and the falciform ligament. Oblique subcostal scans show the internal structure 
of the right lobe with the portal vein, portal vein branches and hepatic veins with the 
segmental anatomy. Additionally gall bladder and intrahepatic bile ducts are pictured. 
The right lobe with the subphrenic region can be demonstrated with intercostals 
sections. For these scans the transducer can be put on patients intercostal spaces, 
especially if the subcostal, epigastric view is limited due to bowel gas. 
 
To evaluate the liver echogenity, the echo of the liver parenchyma was compared 
with the echogenity of the kidneys. Normally, the liver echogenity is very similar to 
the echogenitiy of the kidney 
parenchyma. In patients with 
steatotic livers, the liver 
parenchyma is hyperechoic and 
seems so be whiter then kidney 
parenchyma. Figure 20 shows a 
steatotic liver compared to a  
         normal kidney. 
 
 
 
Fig. 20: Ultrasound image with steatotic liver and normal kidney parenchyma. 
Source: World J Gastroenterol. 2008 June 14; 14(22): 3476-3483. 
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To determine the maximum flow in the portal vein a duplex sonography was also 
performed. Duplex sonography uses the effect of moving fluid within a vessel that 
causes a shift of the echoreflex frequency. This shift can be detected by the 3.5 MHz 
transducer and the ultrasound machine can convert this signal into a color-coded 
scale. By this scale and its typical continuous duplex signal the portal vein can be 
identified and direction and flow strength of the portal vein can be examined. Figure 
21 shows an ultrasound image showing the typical flow signal of the portal vein.  
 
 
 
After identification of the portal vein the mean and the maximum flow of portal vein 
can be detected by using the power duplex ultrasound. For that a detector is placed 
into the ROI (region of interest) and the portal flow is converted into a time-flow-
Fig. 21: Duplex ultrasound with color-coded scale and time-flow diagram of the portal vein. 
Source: Mullan C P et al. AJR 2010;195:1438-1443 
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diagram (see Fig. 21). To avoid wrong results the angle of the flow direction has to 
be corrected (see the white line on red background which represents the flow 
direction). After correction of the flow angel the flow velocity can be read from the 
flow-time-scale (see the vertical scale on the right side of the ultrasound images, Fig. 
21). The measurement is performed in expiratory position with the transducer in 
normal pressure on the patient. Normal flow velocity in the portal vein is  
15 – 30 cm/ s. 
 
Using the 7.5 MHz the thickness of the fat layer over the right costal arch and 
periumbilcal was measured and documented in the examination form of this study, 
together with all the other results of the examination using the 3,5 MHz transducer. 
 
  Page 56 of 65 
 
2.5 Serum analysis of RANTES 
RANTES in human sera was assessed by sandwich enzyme-linked immunosorbent 
assay (ELISA) using the human CCL5 DuoSet ELISA development kit (R&D Systems 
Inc., MN, USA, catalog number DY278). In this ELISA test samples were used 
undiluted. 
 
An ELISA test, also known as enzyme immunoassay (EIA), is a biochemical 
technique to detect the presence of an antibody or antigen in a sample based on an 
enzymatic color change reaction. With the help of an ELISA test, proteins, viruses as 
well as antibodies, hormons, toxins and other can be detected in a sample.  
 
In a double-antibody-sandwich-ELISA two antibodies are used which both specifically 
bind the antigen to be detected. According to the manufacturers’ instructions the 
implementation of this test is as follows: In the first step, the first monoclonal antibody 
– the coating or capture antibody – (in this case specific for RANTES) is tied to a 
microtiter plate (in this case a 96 well polystyrene microplate coated with a mouse 
monoclonal antibody against RANTES). In the second step the sample with the 
antigen is added to that plate and given some time to adhere to the plastic. In this 
time the coating antibody bound to the plate binds the antigen in the sample. In the 
third step, the plate is washed to remove all unbound proteins. Thus, only the 
antigens bound to the coating antibody remain on the plate.  In the fourth step, the 
second polyclonal antibody - the detection antibody – is added to the plate (in this 
case specific for RANTES). The detecting antibody binds another epitope of the 
antigen than the capture antibody. The detecting antibody has an attached enzyme 
(in this case horseradish peroxidase). After incubating a short time an antibody-
antigen-antibody-complex exists when the detecting antibody binds the antigen-
  Page 57 of 65 
 
capture antibody complex. That is where the name “sandwich-ELISA” comes from. 
After a second washing in order to remove unbound antibodies, the suitable enzyme 
substrate is added to the plate. Often, this substrate changes its colour upon reaction 
with the enzyme. The color change shows that the second antibody has bound to 
primary antibody. The higher the concentration of the antigen in the probe the 
stronger the color change. Then a spectrometer is used to give quantitative values 
for the color strength. For clarification, figure 22 shows a scheme of a sandwich 
ELISA (Description of Human CCL5/ Rantes DuoSet (Catalogue Number DY279, 
R&D Systems Inc.). 
 
 2.6 Statistical analysis 
For continuous variables results are expressed as means ± standard deviation. One-
way analysis of variance (F test) was used to compare means. Correlations between 
categorical variables were assessed constructing contingency tables and applying 
the (% test. To identify independent predictors of NAFLD, the significance value of the 
Fig. 22: (1) Plate is coated with a capture antibody; (2) sample is added, and any antigen present binds to capture antibody; 
(3) detecting antibody is added, and binds to antigen; (4) enzyme-linked secondary antibody is added, and binds to 
detecting antibody; (5) substrate is added, and is converted by enzyme to detectable form. 
Quelle: Jeffrey M. Vinocur 2006, (Multi-license with GFDL and Creative Commons CC-BY 2.5)!
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Wald statistic in a multivariate logistic regression model was used. A p-value < 0.05 
was considered significant. Statistical analysis was performed on a PC using SPSS 
15.0 software. 
 
Statistical analysis were performed using SPSS version 15.0 (SPSS, Chicago, IL, 
USA) and GraphPad Prism Software (GraphPad Software, Inc., San Diego, USA). 
Results are expressed as means ± standard error (range). Comparisons between 
groups were made using one way analysis of variance (with Bonferroni correction for 
multiple comparisons). P-values <0.05 were considered as statistically significant.  
 
The data of this study were correlated with analysis of murine models of NAFLD and 
an in vitro model of hepatic lipid accumulation. Together these data have been 
successfully published (Kivovski 2010).  
 
In the following, the data of the human study, which are the basis of this dissertation, 
are presented (in results) and discussed (in discussion) together. Methods applied for 
in vitro studies and assessment of the murine model are described in detail in the 
above mentioned publication (Kivovski 2010). 
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III. RESULTS 
Increased RANTES serum levels in patients with non-alcoholic fatty liver  
Recently, we have described a cohort of patients 
with referral for sonographic examination of the 
abdomen and ultrasound-diagnosed NAFLD 
(Kivovski 2010). Analysis of serum levels of 
RANTES revealed slightly but significantly elevated 
RANTES levels in patients with ultrasound-
diagnosed NAFLD (n=45; mean: 85.9 ng/ml, SEM 
3.7 ng/ml,) in comparison to the control group 
(n=61; 60.1 ng/ml,  SEM 2.9 ng/ml; p<0.001), (Fig. 
23). 
  
 
Correlation between fat metabolism markers and RANTES serum levels 
Table 8 shows the correlation coefficients of different fat metabolism markers and 
RANTES serum levels using Spearman’s Rho test. 
Table 8: Correlation between fat metabolism markers and RANTES 
Correlation Coefficient -0.021 
Sig. (2-tailed) 0.811 
Triglyceride 
N 137 
Correlation Coefficient 0.038 
Sig. (2-tailed) 0,661 
Full cholesterol 
N 138 
Correlation Coefficient -0.024 
Sig. (2-tailed) 0.804 
HDL-Cholesterol 
N 111 
Correlation Coefficient 0.121 
Sig. (2-tailed) 0,157 
LDL-Cholesterol 
N 138 
Correlation Coefficient -0.238 
Sig. (2-tailed) 0.005 
VLDL-Cholesterol 
N 137 
 
Fig. 23: Serum RANTES levels in patients 
with NAFLD. Serum RANTES levels in 
patients with ultrasound (US) diagnosed fatty 
liver compared to a control (ctr.) group of 
patients with normal sonographic liver 
appearance. (*p<0.05 compared to control). 
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We could not find any significant relations between RANTES serum levels and 
triglyzeride concentration, full cholesterol, HDL-Cholesterol and LDL-Cholesterol. 
Interestingly, there was a weak, negative correlation between VLDL-Cholesterol and 
RANTES serum levels. This might be a statistical phenomenon because of our low 
number of cases or increased RANTES levels go along with decreased VLDL-
Cholesterol serum concentration by so far unknown mechanisms. 
 
Correlation between liver function tests and RANTES serum levels 
Table 9 shows the correlation coefficients of different liver function tests and 
RANTES serum levels using Spearman’s Rho test. 
Table 9: Correlation between liver function tests and RANTES 
Correlation Coefficient -0.044 
Sig. (2-tailed) 0.607 
GOT (AST) 
N 138 
Correlation Coefficient 0.073 
Sig. (2-tailed) 0.397 
GPT (ALT) 
N 138 
Correlation Coefficient -0.126 
Sig. (2-tailed) 0.162 
Gamma-GT 
N 124 
Correlation Coefficient 0.094 
Sig. (2-tailed) 0.275 
Alcalic Phosphatase 
N 136 
Correlation Coefficient 0.134 
Sig. (2-tailed) 0.118 
Bilirubin 
N 136 
Correlation Coefficient -0.097 
Sig. (2-tailed) 0.315 
Lipase 
N 110 
Correlation Coefficient 0.175 
Sig. (2-tailed) 0.068 
Total protein 
N 109 
Correlation Coefficient 0.136 
Sig. (2-tailed) 0.156 
CHE 
N 111 
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We could not find significant correlations between RANTES serum levels on the one 
hand and GOT (AST), GPT (ALT), Gamma-GT, alcalic phosphatase, Bilirubin, 
Lipase, total protein and cholinesterase on the other.  
 
 
Correlation between iron metabolism markers and RANTES serum levels 
Table 10 shows the correlation coefficients of some iron metabolism markers and 
RANTES serum levels using Spearman’s Rho test. 
Table 10: Correlation of iron metabolism markers and RANTES 
Correlation Coefficient 0,036 
Sig. (2-tailed) 0,839 
Fe3+ 
N 34 
Correlation Coefficient 0,146 
Sig. (2-tailed) 0,279 
Ferritin 
N 57 
Correlation Coefficient 0,133 
Sig. (2-tailed) 0,305 
Transferrin 
N 61 
Correlation Coefficient -0,145 
Sig. (2-tailed) 0,266 
Transferrin saturation 
N 61 
 
We did not find any significant correlations between RANTES serum levels and 
typical iron metabolism markers like Fe3+, ferritin, transferring and transferrin 
saturation. 
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Correlation between physical examination findings and RANTES serum levels 
Table 11 shows the correlation coefficients of physical examination findings and 
RANTES serum levels using Spearman’s Rho test. 
Table 11: Correlation between physical examination findings and RANTES serum levels 
Correlation Coefficient -0.158 
Sig. (2-tailed) 0.063 
Age 
N 139 
Correlation Coefficient 0.016 
Sig. (2-tailed) 0.854 
Hip circumference in cm 
N 138 
Correlation Coefficient 0.096 
Sig. (2-tailed) 0.264 
Waist circumference in cm 
N 138 
Correlation Coefficient -0.07 
Sig. (2-tailed) 0.414 
waist to hip ratio 
N 138 
Correlation Coefficient -0.205 
Sig. (2-tailed) 0.015 
Systolic blood pressure in mmHg 
N 140 
Correlation Coefficient -0.1 
Sig. (2-tailed) 0.24 
Diastolic blood pressure in mmHg 
N 140 
Correlation Coefficient 0.034 
Sig. (2-tailed) 0.688 
Heart rate 
N 140 
 
There was no significant correlation between diastolic blood pressure and RANTES 
serum levels. However, we found a weak negative correlation between RANTES 
serum levels and systolic blood pressure. Also here, the most likely reason for this is 
a statistical phenomenon due to a too low sample count. 
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Correlation between ultrasound examination findings and RANTES serum levels 
Table 12 shows the correlations coefficients of ultrasound examination findings and 
RANTES serum levels using Spearman’s Rho test. 
Table 12: Correlation between ultrasound examination findings and RANTES serum levels 
Correlation Coefficient 0.069 
Sig. (2-tailed) 0.418 
Liver size in right MCL 
N 140 
Correlation Coefficient 0.109 
Sig. (2-tailed) 0.197 
Fat layer on right costal arch 
N 141 
Correlation Coefficient 0.143 
Sig. (2-tailed) 0.092 
Fat layer paraumbilical 
N 141 
Correlation Coefficient -0.08 
Sig. (2-tailed) 0.347 
Portal vein flow in cm/ s 
N 139 
 
We could not find any significant correlation between RANTES serum levels and 
ultrasound examination findings, i.e. liver size measured in medioclavicular line, 
thickness of the fat layer on the right costal arch, fat layer measured in the 
paraumbilical region and portal vein flow.  
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IV. DISCUSSION 
The chemokine RANTES has been shown to play a central role in the pathogenesis 
and progression of chronic liver disease, however, present information regarding its 
expression in nonalcoholic fatty liver disease (NAFLD) is sparse (Wasmuth 2010). 
 
RANTES has been shown to be expressed by hepatocytes and is up-regulated in 
response to inflammatory conditions (Zeremski 2007, Afford 1998, Rowell 1997, 
Ohashi 2009). Further, our group has shown that lipid accumulation does also dose-
dependently induced RANTES expression in primary human hepatocytes in vitro. 
Thus, pure hepatocellular steatosis leads to increased hepatic RANTES expression. 
In line with this, we observed that feeding a high-fat diet induced hepatic RANTES 
expression in the absence of significant hepatic inflammation or fibrosis in mice. This 
finding further confirms steatotic hepatocytes but not infiltrating inflammatory cells or 
activated hepatic stellate cells as main cellular sources of elevated hepatic RANTES 
expression in high-fat diet fed mice (Kivovski 2010). 
 
Nevertheless, it has to be considered that obesity frequently leads to up-regulation of 
cytokines as a part of a systemic state of low inflammation not only in the liver but 
also in (visceral) adipose tissue, which is another important source of circulating 
cytokines including RANTES (Skurk 1009). However, in our study, RANTES 
expression in visceral fat of mice, which were fed with a high-fat diet, was similar to 
the control group. This suggests that at least under these experimental conditions the 
fatty liver but not adipose tissue is the source of elevated (circulating) RANTES levels 
(Kivovski 2010). Taken together this data and the known pathophysiological role of 
RANTES in other chronic liver diseases indicate that steatosis-triggered RANTES 
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production by hepatocytes is an early event during the natural course of NAFLD and 
may be involved, along with other factors/cytokines, in the progression of fatty liver to 
significant inflammation, e.g. NASH.  
 
Interestingly, patients in the present study with US-diagnosed NAFLD had 
significantly elevated RANTES serum levels compared to the control group, although 
this increase was only moderate compared to the induction of RANTES mRNA 
expression in in vitro lipid loaded hepatocytes and murine fatty livers. However, 
despite US examination can be adequately used to assess hepatic steatosis (Joseph 
1991, Saverymuttu 1986), it has to be considered that the reliable threshold is 
approximately 30% fat in the hepatic tissue (Saadeh 2002). Thus, it is likely that a 
significant number of patients in the control group also had hepatic steatosis below 
the US-detection level. NAFLD is generally defined by lipid deposition greater than 5-
10% of the liver weight (Neuschwandner-Tetri 2003, Caldwell 2004). Further, the 
above mentioned in vitro data (Kivovski 2010) indicate that even minimal 
hepatocellular lipid accumulation leads to increased RANTES levels. Conversely, 
despite the lack of histological examination in this hospital cohort of randomly 
selected patients, it can be estimated from epidemiological studies (Bellentani 2010), 
that only a minority of cases had significant hepatic inflammation (e.g. criteria for 
NASH), which may have caused elevated RANTES levels. 
 
In summary, this study indicates that hepatic steatosis causes an up-regulation of 
hepatic RANTES expression. Noteworthy, increased expression of RANTES in 
response to hepatocellular lipid accumulation appears to occur in the absence of 
relevant hepatic inflammation. This finding further indicates that hepatic steatosis per 
se has pathophysiological relevance and should not be considered as benign. 
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2. Summary 
 
Einführung 
Die nicht-alkoholische Fettlebererkrankung beschreibt ein weites Spektrum von 
Erkrankungen, das von einfacher Leberverfettung (Steatosis) bis zu nicht-
alkoholischer Steatohepatitis, die mit als Hauptursache der nicht-cholestatischen 
Leberzirrhose und damit als Vorstufe eines Leberzellkarzinomes gilt.  
 
Die genaue Ursache der nicht-alkoholischen Fettleberhepatitis ist nicht genau 
bekannt. Am wahrscheinlichsten gilt die sog. Zwei-Schritte-Hypothese, die berets 
1998 von Day und James vorgestellt wurde: der erste Schritt ist dabei die 
Insulinresistenz, der zweite Schritt sind necroinflammatorische Mechanismen, die 
dann zum Leberparenchymschaden führen.  
 
Chemokine sind eine große Familie chemotaktischer Zytokine, deren Mitglieder 
strukturelle Ähnlichkeiten in ihrer Sekundärstruktur aufweisen. Man unterscheidet 
zwei Gruppen von Chemokinen: pro-inflammatorische und homöostatische Zytokine.  
 
RANTES (Regulated upon Activation, Normal T-Cell Expressed and Secreted) oder 
CCL-5 gehört zu der Gruppe der CC-Chemokine, da es zwei aufeinanderfolgende 
Cystein-Resten in seiner Sekundärstruktur aufweist. RANTES ist ein pro-
inflammatorisches Chemokin, welches von den meisten Geweben 
physiologischerweise nicht produziert wird.  
 
Berres et al. konnten in ihrer Studie zeigen, dass RANTES pro-fibrotische 
Eigenschaften bei Entstehung der Leberfibrose hat. Die Expression von RANTES 
mRNA zeigte einen signifikanten Zusammenhang mit höheren Stadien der 
Leberfibrose und der NASH (Nicht-alkoholische Steatohepatitis).  
 
Ziel dieser Studie war es, den Zusammenhang zwischen dem Grad der Steatosis 
hepatis und RANTES-Serumspiegeln zu evaluieren. 
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Patienten und Methoden 
Beginn der Datensammlung war im Februar 2009. Stationäre und ambulante von 
verschiedenen Abteilungen des Uniklinikums Regensburg, die rountinemäßig im 
Ultraschallzentrum des Uniklinikums untersucht werden sollten, wurden in die Studie 
eingeschlossen. Nach Ausschluss aller Patienten mit Ausschlusskriterien (Patienten 
mit bösartigen Erkrankungen, anderen Lebererkrankungen, mit Aszites oder 
chronisch-entzündlichen Darmerkrankungen, mit Alkhol- oder Drogenabusus oder 
Patienten, die Medikamente einnehmen, die eine Steatosis hepatis induzieren 
können) blieb eine Gruppe von 155 Patienten.  
 
Mit allen Patienten wurde ein Anamnesegespräch durchgeführt und die Ergebnisse 
anschließend in einem Anamnesebogen dokumentiert (Geschlecht, 
Vorerkrankungen, Medikamente, Familienanamnese, Diabetes, Lebererkrankungen, 
Fettstoffwechselerkrankungen, Tumorerkrankungen, Alkohol-, Nikotin- und 
Drogenkonsum). Anschließend wurde eine körperliche Untersuchung durchgeführt 
(Bestimmung von Größe, Gewicht, Hüft- und Beckenumfang, Blutdruckmessung und 
Bestimmung der Herzfrequenz.  
 
Außerdem wurde eine Blutabnahme durchgeführt. Die weißen Serumröhrchen 
wurden unmittelbar nach Blutabnahme zentrifugiert und das Zentrifugat zunächst in 
10 Eppendorff-Cups aliquotiert und anschließend tiefgefroren. Durch das Institut für 
klinische Chemie des Uniklinikums Regensburg wurden folgende Blutwerte 
bestimmt: AST, ALT, #-GT, Blutstoffwechselparameter, Albumin, Gesamtprotein, 
Bilirubin, Cholinesterase, alkalische Phosphatase und Nüchternglukose).  
 
Anschließend erfolgte eine Ultraschalluntersuchung und Dokumentation in einem 
Standard-Untersuchungsprotokoll. Es wurden dabei folgende Merkmale untersucht: 
Lebergröße in der MCL, Ausschluss von Ascites, Bestimmung der Leberechogenität, 
der –binnenstruktur, der Leberoberfläche sowie ihrer Kompressibilität, Suche noch 
fokalen Minderverfettungen und anderen Leberraumforderungen, Bestimmung des  
Körperfettes über dem rechten Rippenbogen und periumbilikal und Bestimmung des 
Pfortaderflusses. 
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Die Serumanalyse von RANTES erfolgte in den Forschungslaboren von Herrn Prof. 
Hellerbrand mittels einem Sandwich-ELISA (CCL5 DuoSet ELISA development kit; 
R&D Systems). 
 
Ergebnisse 
Die RANTES-Serumspiegeln waren in der Patientengruppe mit Ultraschall-
diagnostizierter Fettleber gering, aber signifikant (p< 0,001) erhöht (85,9 ng/ ml) 
gegenüber der Kontrollgruppe mit normalem Leberparenchym in der 
Ultraschalluntersuchung (60,1 ng/ ml).  
 
Für die Fettstoffwechselwerte (Triglyzeride, Gesamtcholesterin, HDL, LDL) und 
RANTES sowie für die Leberwerte (ALT, AST, #GT, alkalische Phosphatase, 
Bilirubin, Lipase, Gesamtprotein und Cholinesterase) und RANTES sowie für 
Eisenstoffwechselparameter (Fe3+, Ferritin, Transferrin und Transferrinsättigung) und 
RANTES konnten keine signifikanten Zusammenhänge nachgewiesen werden.  
 
Es konnte auch kein siginifikanter Zusammenhang zwischen den Ergebnissen der 
körperlichen Untersuchung (Alter, Hüft- und Beckenumfang, Blutdruck und 
Herzfrequenz) und RANTES sowie den übrigen Befunden der 
Ultraschalluntersuchung (Lebergröße, Fettschicht über dem rechen Rippenbogen 
und periumbilikal, Pfortaderfluss) und RANTES nachgewiesen werden. 
 
Diskussion 
RANTES scheint eine zentrale Rolle in der Entstehung und der Fortschreiten der  
chronischen Lebererkrankungen zu spielen. Es konnte bereits gezeigt werden, dass 
RANTES von Hepatozyten vermehrt bei Vorliegen einer Entzündung exprimiert wird.  
 
Wir konnten in unserer Studie zeigen, dass die Ansammlung von Fett in-vitro 
ebenfalls die vermehrte Expression von RANTES bewirkt. Im Mausmodel konnte 
gezeigt werden, dass RANTES in Abwesenheit von hepatischer Entzündung oder 
Leberfibrose vermehrt exprimiert wird. Dies bestätigt, dass RANTES hauptsächlich 
von verfetteten Hepatozyten und nicht von pro-entzündlichen Zellen oder aktivierten 
Sternzellen produziert wird.  
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Skurk konnte zeigen, dass auch das Fettgewebe ein wichtiger Produktionsort für 
zirkulierende Zytokine, unter anderem auch RANTES, ist.  Dennoch war die 
RANTES-Expression im Mausmodel bei Mäusen mit NASH gegenüber der 
Kontrollgruppe nicht erhöht. Dies zeigt möglicherweise, dass die Fettleber und nicht 
das Fettgewebe die Hauptquelle für erhöhte RANTES-Serumspiegel ist.  
 
Zusammenfassend lässt sich sagen, dass unsere Studie darauf hin deutet, dass die 
Steatosis hepatis zu einer Erhöhung der RANTES-Expression führt. Diese Erhöhung 
der RANTES-Expression tritt auch in Abwesenheit von relevanter hepatischer 
Entzündung auf. Dies deutet daraufhin, dass die Fettleber an sich schon eine 
pathophysiologische Relevanz hat und nicht als benigen erachtet werden sollte. 
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